You are here: Industry Insights > COPD

News List

COPD Treatment Landscape David Orchard-Webb
January 19, 2024
The comprehensive management of Chronic Obstructive Pulmonary Disease (COPD) requires a multi-faceted approach encompassing medications, lifestyle adjustments, and surgical interventions.
FDA Approves First Generic of Symbicort to Treat Asthma and COPD FDA
March 17, 2022
Today, the U.S. Food and Drug Administration approved the first generic of Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol for the treatment of two common pulmonary health conditions...
Enrol call: Verona recruits 800 patients for COPD trial pharmatimes
January 24, 2022
The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed with COPD.
CHMP opinions: EMA refuses asthma label expansion for GSK’s COPD drug Trelegy Ellipta pharmaceutical-technology
March 02, 2021
The European Union’s healthcare regulator the European Medicines Agency (EMA) has decided against a label expansion for GlaxoSmithKline (GSK)’s drug Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) to include asthma.
Inhaled hyaluronan shows promise in COPD europeanpharmaceuticalreview
February 03, 2021
A study shows inhaling hyaluronan is effective as a treatment for severe flares of chronic obstructive pulmonary disease (COPD).
EU for AZ' COPD maintenance therapy pharmatimes
December 15, 2020
AstraZeneca’s Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) has been approved in the EU for maintenance treatment in adults with moderate to severe chronic obstructive pulmonary disease (COPD).
Zydus Cadila launches COPD drug in India expresspharma
October 09, 2020
Forglyn pMDI is priced at Rs 495 per pack and has been developed in-house using Zydus’ innovations in formulation technology.
Verona Pharma launches late-stage COPD trial programme pharmatimes
September 27, 2020
Verona Pharma has initiated phase III trials to evaluate the safety and efficacy of nebulised ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
GSK gets US FDA approval for Trelegy Ellipta to treat asthma, COPD expresspharma
September 18, 2020
Trelegy is the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.
Verona progresses PhII trial of COPD inhaler pharmatimes
August 19, 2020
Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.